Non-enveloped virus inactivation composition

Abstract

To provide a non-enveloped virus inactivation composition having a high inactivation effect on non-enveloped viruses.SOLUTION: A non-enveloped virus inactivation composition comprises (a) a positive ion surfactant, (b) an aromatic alcohol having a CLogP of 1.4-2.0, and water.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a composition for inactivating non-enveloped viruses, a method for inactivating non-enveloped viruses, an enhancer for the non-enveloped virus inactivation effect of cationic surfactants, and a method for enhancing the non-enveloped virus inactivation effect of cationic surfactants. [Background technology]

[0002] Viruses can be broadly classified into enveloped viruses and non-enveloped viruses based on differences in their membrane structure. SARS viruses such as COVID-19 (SARS-CoV-2), which causes the novel coronavirus infection that has become a major problem worldwide in recent years, and influenza viruses are classified as enveloped viruses, while norovirus is classified as a non-enveloped virus. Enveloped viruses have a lipid membrane (envelope) on their surface and a membrane structure consisting of a capsid protein inside, so they can be easily inactivated by alcohol or soap that acts on the lipid membrane. For this reason, alcohol-based preparations with ethanol as the main ingredient are routinely and easily used in homes, public facilities, markets, etc. as a measure against infection. However, non-enveloped viruses do not have an envelope in their membrane structure, but as will be described later, their membrane is composed of a capsid protein that forms a hydrophobic core, making them difficult to destroy with ethanol or soap, and many viruses are difficult to inactivate.

[0003] Viral infections, such as influenza and the common cold, are considered to be effectively prevented by hand and environmental hygiene. Among these, viral acute gastroenteritis and diarrhea are not only confirmed as outbreaks in nursing homes, schools, and hospitals, but are also frequently reported as outbreaks of food poisoning through contaminated food in restaurants and cooking facilities. The viruses that cause these illnesses include non-enveloped viruses such as norovirus, sapovirus, and rotavirus, and infections in children and the elderly can cause severe symptoms. Furthermore, the viruses that cause hand, foot, and mouth disease, a common childhood infection, and foot-and-mouth disease, which causes significant damage to livestock, are also classified as non-enveloped viruses, and hand and environmental hygiene measures are extremely important for preventing these illnesses as well.

[0004] In particular, norovirus is detected not only in Japan but all over the world as a causative agent of nonbacterial food poisoning and acute gastroenteritis. While bacteria such as Staphylococcus aureus and Bacillus cereus have traditionally been known causes of food poisoning, in recent years, food poisoning caused by norovirus, which causes acute gastroenteritis, has become the most common, accounting for about 25% of all food poisoning cases and about half of all cases, and is being viewed as a problem as a virus that causes mass infections. The most well-known route of infection is oral transmission through the consumption of shellfish such as raw oysters, but many secondary infections have also been reported from the virus present on the hands or cooking utensils of people who have touched contaminated food in homes or public facilities, in the vomit or feces of patients, or in the environment surrounding patients. In particular, such secondary infections can lead to mass infections and the spread of infection, and are a major cause of the increase in the number of patients.

[0005] To prevent food poisoning and infection caused by norovirus, it is extremely important to implement hygiene measures such as virus removal and inactivation, as well as hand washing, on floors, walls, food processing equipment, cooking utensils, etc. in mass cooking facilities and kitchen spaces such as catering facilities and restaurants, as well as floors, walls, cooking utensils, furniture, textiles, etc. in homes, and floors, walls, equipment, medical devices, etc. in public facilities. It is desirable that these measures be implemented in a way that is considerate of people and the environment, and is easy to carry out.

[0006] Norovirus is an RNA virus that does not have an envelope (membrane structure), belonging to the Caliciviridae family and the Norovirus genus. It is known to have strong resistance to acid (stomach acid) and can cause infection with a small amount (around 10 to 100 particles). Currently, there are no vaccines or treatments for norovirus, and the only way to prevent norovirus infection is to eliminate or inactivate the virus through washing and disinfecting potentially causative foods, cooking utensils, and hands. However, as mentioned above, norovirus is a non-enveloped virus, and due to its membrane structure, it has strong physicochemical resistance. Therefore, disinfectants containing ethanol or cationic surfactants, which are effective against many bacteria, may not be sufficiently effective against norovirus with general use. For this reason, disinfectants such as chlorine-based bleaches (sodium hypochlorite, etc.), iodine-based disinfectants (povidone-iodine, etc.), aldehyde-based disinfectants (glutaraldehyde, etc.), and peracetic acid preparations are used to inactivate norovirus. However, such disinfectants are highly irritating to humans and corrode metals, so proper use is required. In addition, chlorine-based bleaches have a bleaching effect on the color and pattern of fibers, so their use on textile products and clothing is restricted. Therefore, considering user safety, the objects and situations in which these chemicals are used, there are restrictions on their use in the living environment, on hands, cooking utensils, clothing, etc.

[0007] We have not yet established an antiviral agent that can be used in the same way as ethanol, which is used to inactivate enveloped viruses, for the inactivation of non-enveloped viruses. In the near future, when highly infectious and deadly non-enveloped viruses may emerge, we do not have a simple and effective sanitary measure like those used to inactivate influenza and coronaviruses. Although hypochlorite solutions show excellent inactivation ability against non-enveloped viruses, their strong oxidizing power requires careful handling due to the potential impact on the human body. Furthermore, bleach poses a corrosion problem for metals and other materials.

[0008] In recent years, there has been a demand for means that are less irritating and corrosive or can inactivate viruses that can also be used on textile products. In addition, technologies applying aromatic alcohols as described below have been disclosed. Patent Document 1 discloses a technology of an antiviral agent composition containing a cationic surfactant and benzyl alcohol. Patent Document 2 discloses a technology of a detergent composition containing a quaternary ammonium salt type surfactant and an alcohol-based solvent, which has an excellent virus inactivating effect and little skin irritation, and a composition containing phenoxyethanol is exemplified. Further, Patent Document 3 describes that an antibacterial hand wash composition containing a cationic antibacterial agent and phenoxyethanol can sterilize non-enveloped and / or enveloped viruses. On the other hand, Patent Document 4 discloses a technology of a laundry disinfectant, and a disinfectant detergent composition containing a quaternary ammonium salt and an aromatic alcohol has a technology of a disinfectant detergent composition for laundry that is highly effective against bacterial spores.

Prior Art Documents

Patent Documents

[0009]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Summary of the Invention

[0011] The present invention relates to a non-enveloped virus inactivation composition containing (a) a cationic surfactant [hereinafter referred to as component (a)], (b) an aromatic alcohol with a CLogP of 1.4 or more and 2.0 or less [hereinafter referred to as component (b)], and water.

[0012] Furthermore, the present invention relates to a method for inactivating non-enveloped viruses, comprising contacting the above-mentioned non-enveloped virus inactivation composition with a target surface.

[0013] Furthermore, the present invention relates to an enhancer of the non-enveloped virus inactivation effect of cationic surfactants, comprising (b) an aromatic alcohol with a CLogP of 1.4 or more and 2.0 or less.

[0014] Furthermore, the present invention relates to a method for enhancing the non-enveloped virus inactivation effect of a cationic surfactant by (a) including an aromatic alcohol with a CLogP of 1.4 or more and 2.0 or less in a non-enveloped virus inactivation composition containing a cationic surfactant. [Effects of the Invention]

[0015] The present invention provides a non-enveloped virus inactivation composition and a non-enveloped virus inactivation method that have a high inactivation effect against non-enveloped viruses. Furthermore, the present invention provides a cationic surfactant non-enveloped virus inactivation effect enhancer and a method for enhancing the non-enveloped virus inactivation effect of a cationic surfactant, which enhance the inactivation effect of the cationic surfactant against non-enveloped viruses. [Modes for carrying out the invention]

[0016] The reason why the non-enveloped virus inactivation composition of the present invention has a high inactivation effect on non-enveloped viruses is not entirely clear, but it is presumed to be as follows. It is thought that the capsid protein of non-enveloped viruses has a hydrophobic core formed by the inward folding of its hydrophobic side chains. Since this hydrophobic core is not exposed on the surface, it is thought that (a) a cationic surfactant [component (a)] does not easily act on the hydrophobic core. Therefore, it is presumed that by having component (a) and (b) an aromatic alcohol [component (b)] with a CLogP of 1.4 or more and 2.0 or less in the same coexistence, component (b) modifies the hydrophobic core, making it easier for component (a) to act on the hydrophobic core, and thus the effects of the present invention are realized. In this invention, non-enveloped virus inactivation may mean killing non-enveloped viruses or rendering them inactive. Furthermore, the non-enveloped virus inactivation effect refers to killing some or all of the non-enveloped viruses, or rendering them inactive, toxic, or otherwise inactive.

[0017] [Composition for inactivating non-enveloped viruses] The non-enveloped virus inactivation composition of the present invention contains (a) a cationic surfactant [component (a)], (b) an aromatic alcohol with a CLogP of 1.4 or more and 2.0 or less [component (b)], and water.

[0018] <(a) Components> (Component (a) is a cationic surfactant. Examples of component (a) include quaternary ammonium salt type surfactants. Component (a) may be one or more selected from cationic surfactants.) (As the quaternary ammonium salt type surfactant of component (a), one or more selected from the compounds represented by the following general formula (a1) and the compounds represented by the following general formula (a2) are preferred.)

[0019] [Chemical formula]

[0020] [In the formula, R 1a is an aliphatic hydrocarbon group having 8 to 18 carbon atoms, R 2a is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms, R 3a and R 4a are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X - is an anion.]

[0021] [Chemical formula]

[0022] [In the formula, R 5a is an aliphatic hydrocarbon group having 8 to 18 carbon atoms, R 6a and R 7a are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X - is an anion.]

[0023] In general formula (a1), R 1aThe number of carbon atoms is preferably 9 or more, more preferably 10 or more, even more preferably 12 or more, and preferably 16 or less, and more preferably 14 or less, from the viewpoint of non-enveloped virus inactivation effect. 1a The group is preferably an alkyl group or an alkenyl group, with alkyl groups being preferred. In general formula (a1), R 2a This group is selected from aliphatic hydrocarbon groups having 8 to 18 carbon atoms, alkyl groups having 1 to 3 carbon atoms, and hydroxyalkyl groups having 1 to 3 carbon atoms. R 2a However, if it is an aliphatic hydrocarbon group with 8 to 18 carbon atoms, R 2a From the viewpoint of inactivating non-enveloped viruses, alkyl or alkenyl groups with 8 or more carbon atoms are preferred, more preferably 10 or more, more preferably 16 or fewer, more preferably 14 or fewer, and even more preferably 12 or fewer carbon atoms are preferred, with alkyl groups being preferred. R 2a However, if it is an alkyl group with 1 to 3 carbon atoms, R 2a Examples include methyl groups, ethyl groups, and propyl groups. 2a However, if the group is selected from hydroxyalkyl groups with 1 to 3 carbon atoms, R 2a Examples include hydroxymethyl groups, hydroxyethyl groups, and hydroxypropyl groups.

[0024] In general formula (a1), R 3a and R 4a Each of these groups is independently selected from alkyl groups having 1 to 3 carbon atoms and hydroxyalkyl groups having 1 to 3 carbon atoms. 3a and R 4a Preferably, each of these groups is independently selected from alkyl groups having 1 to 3 carbon atoms. Examples of alkyl groups having 1 to 3 carbon atoms include methyl, ethyl, and propyl groups. Examples of hydroxyalkyl groups having 1 to 3 carbon atoms include hydroxymethyl, hydroxyethyl, and hydroxypropyl groups.

[0025] In general formula (a1), X -It is an anion. Examples of anions include halogen ions, such as chloride ions, bromide ions, and iodide ions. Also, examples of alkyl sulfate ions having 1 to 3 carbon atoms include methyl sulfate ions, ethyl sulfate ions, and propyl sulfate ions.

[0026] Preferred compounds of the general formula (a1) include one or more selected from N-alkyl-N,N,N-trimethylammonium salts having 12 to 18 carbon atoms in the alkyl group, N,N-dialkyl-N,N-dimethylammonium salts having 8 to 16 carbon atoms in the alkyl group, and N-alkyl-N,N-dimethyl-N-ethylammonium salts having 12 to 16 carbon atoms in the alkyl group.

[0027] In general formula (a2), R 5a R is an aliphatic hydrocarbon group having 8 to 18 carbon atoms. 5a The number of carbon atoms is preferably 8 or more, more preferably 12 or more, preferably 18 or less, more preferably 16 or less, and even more preferably 14 or less, from the viewpoint of non-enveloped virus inactivation effect. 5a The group is preferably an alkyl group or an alkenyl group, with alkyl groups being preferred.

[0028] In general formula (a2), R 6a and R 7a Each of these groups is independently selected from alkyl groups having 1 to 3 carbon atoms and hydroxyalkyl groups having 1 to 3 carbon atoms. 6a and R 7a Preferably, each of these groups is independently selected from alkyl groups having 1 to 3 carbon atoms. Examples of alkyl groups having 1 to 3 carbon atoms include methyl, ethyl, and propyl groups. Examples of hydroxyalkyl groups having 1 to 3 carbon atoms include hydroxymethyl, hydroxyethyl, and hydroxypropyl groups.

[0029] In general formula (a2), X -It is an anion. Examples of anions include halogen ions, such as chloride ions, bromide ions, and iodide ions. Also, examples of alkyl sulfate ions having 1 to 3 carbon atoms include methyl sulfate ions, ethyl sulfate ions, and propyl sulfate ions.

[0030] Specific examples of compounds of general formula (a2) include N-dodecyl-N,N-dimethyl-N-benzylammonium salt, N-tridecyl-N,N-dimethyl-N-benzylammonium salt, N-tetradecyl-N,N-dimethyl-N-benzylammonium salt, N-pentadecyl-N,N-dimethyl-N-benzylammonium salt, N-hexadecyl-N,N-dimethyl-N-benzylammonium salt, N-dodecyl-N,N-diethyl-N-benzylammonium salt, N-tridecyl-N,N-diethyl-N-benzylammonium salt, and N-tetradecyl-N,N-diethyl-N-benzylammonium salt. Examples include one or more compounds selected from ammonium salt, N-pentadecyl-N,N-diethyl-N-benzylammonium salt, N-hexadecyl-N,N-diethyl-N-benzylammonium salt, N-dodecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-tridecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-tetradecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-pentadecyl-N-methyl-N-ethyl-N-benzylammonium salt, and N-hexadecyl-N-methyl-N-ethyl-N-benzylammonium salt.

[0031] (a) The component is preferably a quaternary ammonium salt type surfactant having one or two alkyl groups with 8 to 16 carbon atoms, and the remainder being a group selected from alkyl groups with 1 to 3 carbon atoms, hydroxyalkyl groups with 1 to 3 carbon atoms, and benzyl groups. For example, component (a) is given by the general formula (a1), R 1a However, it is an alkyl group having 8 or more carbon atoms and 16 or less, R 2a However, it is a group selected from alkyl groups having 8 to 16 carbon atoms, alkyl groups having 1 to 3 carbon atoms, and hydroxyalkyl groups having 1 to 3 carbon atoms, R 3aand R 4a However, each is independently selected from alkyl groups having 1 to 3 carbon atoms and hydroxyalkyl groups having 1 to 3 carbon atoms, X - Compounds in which R is an anion, and in general formula (a2), 5a However, it is an alkyl group having 8 or more carbon atoms and 16 or less, R 6a and R 7a However, each is independently selected from alkyl groups having 1 to 3 carbon atoms and hydroxyalkyl groups having 1 to 3 carbon atoms, X - It is preferable to select one or more compounds in which the compound is an anion.

[0032] <(b) Component> (b) Component is an aromatic alcohol with a (b)CLogP of 1.4 or more and 2.0 or less. Component (b) acts on the capsid protein that forms the hydrophobic core on the surface of non-enveloped viruses and is an important component in loosening its rigid structure. By using component (b) in combination with component (a), component (a) acts more advantageously on non-enveloped viruses. Component (b) may be one or more selected from the above aromatic alcohols. (b) The CLogP of component (b) is 1.4 or higher, preferably 1.5 or higher, and 2.0 or lower, and may be 1.95 or lower, from the viewpoint of non-enveloped virus inactivation effect. (b) Component may be a monohydric aromatic alcohol or a polyhydric aromatic alcohol, and a monohydric aromatic alcohol is preferred from the viewpoint of non-enveloped virus inactivation effect.

[0033] (b) Component (b) may be an aromatic alcohol having a molecular weight of preferably 120 or more, preferably 200 or less, more preferably 175 or less, and even more preferably 150 or less, from the viewpoint of non-enveloped virus inactivation effect.

[0034] (b) The component is preferably one or more compounds selected from compounds represented by the following general formula (b1) (provided that the CLogP is between 1.4 and 2.0).

[0035] [ka]

[0036] [In the formula, R 1b R is a hydrocarbon group having 1 to 3 carbon atoms. 1b The OH group bonded to R 1b It may be bonded to any of the carbon atoms that make up the molecule. 2b R is a hydrocarbon group having 1 or 2 carbon atoms, which may be bonded to a benzene ring via an oxygen atom. 1b It may be combined with other elements to form a ring. n is a number that is either 0 or 1. 1b and R 2b The total number of carbon atoms is between 2 and 5, preferably between 2 and 3.

[0037] (b) Specifically, the components include the following aromatic alcohols (the numbers in parentheses are the ClogP values): One or more selected from 2-methylbenzyl alcohol (1.553), 3-methylbenzyl alcohol (1.603), 4-methylbenzyl alcohol (1.603), 1-phenyl-1-propanol (1.942), 1-(p-tolyl)ethanol (1.912), 1-hydroxyindan (1.518), 3-phenyl-1-propanol (1.712), and cinnamyl alcohol (1.608) are examples, with one or more selected from 1-phenyl-1-propanol, 3-phenyl-1-propanol, and cinnamyl alcohol being preferred.

[0038] CLogP is a value that estimates the affinity of an organic compound for water and 1-octanol [P = (concentration of the organic compound in the 1-octanol phase) / (concentration of the organic compound in the aqueous phase)], and can be calculated using a calculation program that uses the fragment value of the atomic group determined by the number of atoms constituting the compound molecule and the type of chemical bond. In this invention, CLogP calculated using ChemDraw ver.18.2 from PerkinElmer is used.

[0039] The non-enveloped virus inactivation composition of the present invention contains water. The water is used in an amount that constitutes the remainder of the composition. For example, deionized water or distilled water can be used.

[0040] <Composition and other ingredients> The non-enveloped virus inactivation composition of the present invention contains component (a) in an amount of preferably 10 ppm or more, more preferably 100 ppm or more, even more preferably 250 ppm or more, from the viewpoint of non-enveloped virus inactivation effect, and preferably 10,000 ppm or less, more preferably 5,000 ppm or less, even more preferably 2,000 ppm or less, even more preferably 1,000 ppm or less, and even more preferably 750 ppm or less, from the viewpoint of economic efficiency. In the present invention, ppm represents the mass ratio (parts per million) of each component to the composition (the same applies hereinafter). The non-enveloped virus inactivation composition containing component (a) in the above range can be suitably used as a composition that acts on non-enveloped viruses without dilution. In this invention, the specification regarding the mass of component (a) shall be the value converted to chloride. Alternatively, the non-enveloped virus inactivation composition may be concentrated in advance and then diluted so that the content of component (a) in the non-enveloped virus inactivation composition at the time of use falls within the above range before being applied to non-enveloped viruses.

[0041] The non-enveloped virus inactivation composition of the present invention contains component (b) in an amount of preferably 0.2% by mass or more, more preferably 0.3% by mass or more, even more preferably 0.4% by mass or more, and even more preferably 0.5% by mass or more, from the viewpoint of non-enveloped virus inactivation effect, and preferably 5.0% by mass or less, more preferably 4.0% by mass or less, even more preferably 3.0% by mass or less, and even more preferably 2.0% by mass or less, from the viewpoint of formulation stability. The non-enveloped virus inactivation composition containing component (b) in the above range can be suitably used as a composition that acts on non-enveloped viruses without dilution. Alternatively, the non-enveloped virus inactivation composition can be concentrated in advance and then diluted so that the content of component (b) in the non-enveloped virus inactivation composition at the time of use falls within the above range before being applied to non-enveloped viruses.

[0042] In the non-enveloped virus inactivation composition of the present invention, the mass ratio (a) / (b) of the content of component (a) to the content of component (b) is preferably 0.0001 or more, more preferably 0.0002 or more, even more preferably 0.0005 or more, even more preferably 0.0008 or more, even more preferably 0.0010 or more, and preferably 5 or less, more preferably 1 or less, even more preferably 0.1 or less, and even more preferably 0.05 or less.

[0043] The non-enveloped virus inactivation composition of the present invention preferably contains 60% by mass or more, more preferably 80% by mass or more, even more preferably 90% by mass or more, and preferably less than 100% by mass of water, from the viewpoint of non-enveloped virus inactivation effect. The water may be the remainder other than component (a), component (b), and the optional components listed below.

[0044] <(c) component> The non-enveloped virus inactivation composition of the present invention may optionally contain (c) a surfactant [excluding component (a)] [hereinafter referred to as component (c)] in terms of wettability and penetration into the target object. However, since component (c) and the (d) water-soluble organic solvent described later may alter the properties of component (a) and component (b) necessary for solving the problems of the present invention, the effect on the efficacy must be considered when formulating them.

[0045] (c) Examples of components include one or more selected from (c1) anionic surfactants [hereinafter referred to as (c1) component], (c2) nonionic surfactants [hereinafter referred to as (c2) component], (c3) semipolar surfactants [hereinafter referred to as (c3) component], and (c4) amphoteric surfactants [hereinafter referred to as (c4) component].

[0046] (c1) Component may include alkyl sulfate esters with 8 to 22 C1 of the alkyl group, alkylbenzene sulfonic acid with 8 to 22 C1 of the alkyl group, polyoxyalkylene alkyl ether sulfates with 8 to 22 C1 of the alkyl group (the oxyalkylene group is an oxyalkylene group with 2 or 3 C1, preferably an oxyethylene group, and the average number of added moles of oxyalkylene groups is preferably 0.5 to 5, more preferably 0.5 to 3), fatty acids with 8 to 22 C1, and one or more selected from salts thereof. (c1) Component may include alkali metal salts such as sodium and potassium, alkanolamine salts with 2 to 8 C1, alkali metal salts are preferred, sodium salts or potassium salts are more preferred, and sodium salts are even more preferred. (c2) The component may be one or more selected from polyoxyalkylene alkyl ethers with 8 to 22 carbon atoms in the alkyl group (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxyethylene group, and the average number of moles of oxyalkylene groups added is preferably 3 to 50, more preferably 3 to 20) and alkyl glycosides with 8 to 14 carbon atoms in the alkyl group (the average degree of condensation of the sugar skeleton such as glucose is 1 to 5, preferably 1 to 2). (c3) Component includes amine oxide type surfactants having one or more alkyl groups with 8 to 22 carbon atoms, preferably one alkyl group. (c4) Component may include a sulfobetaine-type surfactant having one or more alkyl groups with 8 to 22 carbon atoms, preferably one, or a carbobetine-type surfactant having one or more alkyl groups with 8 to 22 carbon atoms, preferably one.

[0047] The non-enveloped virus inactivation composition of the present invention may contain component (c) to the extent that it does not inhibit the effects of the present invention. From the viewpoint of wettability to the target object, the non-enveloped virus inactivation composition of the present invention may contain component (c) in an amount of preferably 10 ppm or more, preferably 10,000 ppm or less, more preferably 5,000 ppm or less, even more preferably 2,000 ppm or less, even more preferably 1,000 ppm or less, even more preferably 500 ppm or less, and even more preferably 100 ppm or less. From the viewpoint of the non-enveloped virus inactivation effect, it is preferable that the non-enveloped virus inactivation composition of the present invention does not contain component (c). In this invention, when component (c1) is used as component (c), the specification regarding the mass of component (c1) shall be the value converted to the sodium salt.

[0048] Furthermore, the non-enveloped virus inactivation composition of the present invention may contain component (c2) to the extent that it does not inhibit the effects of the present invention. The non-enveloped virus inactivation composition of the present invention may contain component (c2) in an amount of preferably 10 ppm or more, preferably 10,000 ppm or less, more preferably 5,000 ppm or less, even more preferably 2,000 ppm or less, even more preferably 1,000 ppm or less, even more preferably 500 ppm or less, and even more preferably 100 ppm or less, from the viewpoint of wettability to the target object. From the viewpoint of the non-enveloped virus inactivation effect of the present invention, it is preferable that the non-enveloped virus inactivation composition of the present invention does not contain component (c2).

[0049] Based on the above, the non-enveloped virus inactivation composition of the present invention may contain, as a whole, component (c) in an amount of preferably 10 ppm or more, preferably 10,000 ppm or less, more preferably 5,000 ppm or less, even more preferably 2,000 ppm or less, even more preferably 1,000 ppm or less, even more preferably 500 ppm or less, and even more preferably 100 ppm or less. From the viewpoint of the non-enveloped virus inactivation effect, it is preferable that the non-enveloped virus inactivation composition of the present invention does not contain component (c). In addition, component (c) may be introduced into the non-enveloped virus inactivation composition from other components, but if it is in a trace amount that is less than the above concentrations, the non-enveloped virus inactivation composition of the present invention may not contain component (c).

[0050] In the non-enveloped virus inactivation composition of the present invention, the content of component (a) relative to the total content of surfactants contained in the composition may be preferably 40% by mass or more, more preferably 60% by mass or more, even more preferably 80% by mass or more, even more preferably 90% by mass or more, even more preferably 95% by mass or more, and preferably 100% by mass or less, from the viewpoint of non-enveloped virus inactivation effect. The total content of surfactants contained in the non-enveloped virus inactivation composition of the present invention may be the total content of component (a) and component (c).

[0051] <(d) component> The non-enveloped virus inactivation composition of the present invention may optionally contain (d) a water-soluble organic solvent [excluding component (b)] [hereinafter referred to as component (d)], in terms of wettability and penetration into the target object. The water-soluble organic solvent of the present invention refers to a solvent that dissolves in 20 g or more of 100 g of deionized water at 20°C.

[0052] Component (d) is a water-soluble organic solvent other than aromatic alcohols, which is component (b), with a CLogP of 1.4 or more and 2.0 or less. Examples include one or more water-soluble organic solvents selected from hydrocarbon compounds having hydroxyl groups with 2 or more carbon atoms, preferably 3 or more carbon atoms, and 12 or fewer carbon atoms, preferably 10 or fewer carbon atoms, which may have an ether bond. Component (d) can be further classified into the following (d1) to (d4). (d1) One or more selected from the following: polyhydric alcohols having 2 to 4 carbon atoms; (d2) di- or tetraalkylene glycols with 2 to 4 carbon atoms in the alkylene glycol unit; (d3) monoalkoxy (methoxy, ethoxy, propoxy, or butoxy preferred) ethers, phenoxy ethers, or benzooxy ethers of di- or tetraalkylene glycols with 2 to 4 carbon atoms in the alkylene glycol unit; and (d4) monohydric alcohols having 1 to 3 carbon atoms.

[0053] (d) Component may include water-soluble organic solvents other than component (b) that have 2 or more carbon atoms, preferably 3 or more carbon atoms, and 10 or fewer carbon atoms, preferably 8 or fewer carbon atoms. Specifically, (d1) can be ethylene glycol, propylene glycol, glycerin, or isoprene glycol; (d2) can be diethylene glycol or dipropylene glycol; (d3) can be propylene glycol monomethyl ether, propylene glycol monoethyl ether, diethylene glycol monobutyl ether (also called butyl diglycol, etc.), phenoxyethanol, or phenoxytriethylene glycol; and (d4) can be a monohydric alcohol having 1 to 3 carbon atoms, and one or more of these can be used. As component (d), one or more water-soluble organic solvents selected from propylene glycol, dipropylene glycol, diethylene glycol monobutyl ether, phenoxyethanol, phenyl glycol, and propanol are preferred.

[0054] In the non-enveloped virus inactivation composition of the present invention, component (d) may alter the properties of components (a) and (b) in the composition. Therefore, it is preferable to limit the amount of component (d) in the composition, similar to component (c). However, if it is necessary to consider the stability of the composition from a product standpoint, component (d) may be included in a range that does not significantly impair the effects of the present invention. The content of component (d) in the non-enveloped virus inactivation composition of the present invention is preferably 30% by mass or less, more preferably 20% by mass or less, even more preferably 10% by mass or less, even more preferably 5% by mass or less, even more preferably 1% by mass or less, and even more preferably 0.1% by mass or less. From the viewpoint of the non-enveloped virus inactivation effect, it is preferable that the non-enveloped virus inactivation composition of the present invention does not contain component (d). However, if it is necessary to include component (d), it may contain component (d) preferably 0.01% by mass or more, more preferably 0.1% by mass or more, but the content of component (d) should be less than the content of component (b).

[0055] In the present invention, using component (d) may impair the effect of component (b). Therefore, in the non-enveloped virus inactivation composition, the mass ratio (d) / (b) of the content of component (d) to the content of component (b) in the composition is preferably 0 or more, preferably 1 or less, more preferably less than 1, even more preferably 0.1 or less, and even more preferably 0.01 or less. From the viewpoint of the non-enveloped virus inactivation effect, the non-enveloped virus inactivation composition of the present invention preferably does not contain component (d), and the above mass ratio (d) / (b) is preferably 0.

[0056] The non-enveloped virus inactivation composition of the present invention may optionally contain chelating agents, defoaming agents, stabilizers, pH adjusters, dyes, fragrances, and preservatives, to the extent that they do not inhibit the effects of the present invention.

[0057] The viruses targeted by the non-enveloped virus inactivation composition of the present invention are non-enveloped viruses, such as non-enveloped viruses having a capsid protein on its surface that is difficult to inactivate with ethanol, and furthermore, non-enveloped viruses belonging to the genus Norovirus. Non-enveloped viruses may include, for example, single-stranded (+) RNA viruses, single-stranded (-) RNA viruses, double-stranded RNA viruses, single-stranded DNA viruses, and double-stranded DNA viruses that do not have a lipid layer or lipid bilayer on their viral surface. Examples of non-enveloped viruses include, for example, viruses with DNA genomes such as adenoviruses, parvoviruses, papovaviruses, and human papillomaviruses, and viruses with RNA genomes such as rotaviruses, coxsackieviruses, enteroviruses, sapoviruses, noroviruses, polioviruses, echoviruses, hepatitis A virus, hepatitis E virus, rhinoviruses, astroviruses, and bacteriophage MS2. Furthermore, the non-enveloped virus inactivation composition of the present invention is also effective against enveloped viruses. Enveloped viruses may be single-stranded (+) RNA viruses, single-stranded (-) RNA viruses, double-stranded RNA viruses, single-stranded DNA viruses, and double-stranded DNA viruses that have a lipid layer or lipid bilayer on their viral surface. Examples of enveloped viruses include herpesviruses, influenza viruses, paramyxoviruses, rabies viruses, respiratory syncytial viruses, coronaviruses, HIV, smallpox viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, rubella viruses, SARS coronavirus (SARS-CoV), and MERS coronavirus (MERS-CoV). The non-enveloped virus inactivation composition of the present invention can also inactivate these enveloped viruses. The non-enveloped virus inactivation composition of the present invention has a high non-enveloped virus inactivation effect against non-enveloped viruses, and more particularly against non-enveloped viruses belonging to the genus Norovirus.

[0058] The non-enveloped virus inactivating composition of the present invention has a high non-enveloped virus inactivating effect against non-enveloped viruses even in the pH range from acidic to alkaline. The non-enveloped virus inactivating composition of the present invention has an excellent virus inactivating effect even in the pH range from acidic to neutral, which is an effect not found in conventional non-enveloped virus inactivating compositions. The pH of the non-enveloped virus inactivating composition of the present invention at 20 °C can be selected from 0 or more, further 1 or more, further 2 or more, further 3 or more, further 4 or more, and 11 or less, further 10 or less, further 9 or less, further 8 or less, further 7 or less, from the viewpoint of irritation to the skin. The pH of the present invention is measured by the glass electrode method. This pH is measured by the following measurement method.

[0059] <pH Measurement Method> Connect a combined electrode for pH measurement (for example, a glass sliding sleeve type manufactured by Horiba, Ltd.) with the internal solution of the pH electrode being a saturated potassium chloride aqueous solution (3.33 mol / L) to a pH meter (for example, pH / Ion Meter F-23 manufactured by Horiba, Ltd.). Next, fill 100 mL beakers with pH 4.01 standard solution (phthalate standard solution), pH 6.86 (neutral phosphate standard solution), and pH 9.18 standard solution (borate standard solution) respectively, and immerse them in a constant temperature bath at 20 °C for 30 minutes. Immerse the pH measurement electrode in the standard solution adjusted to a constant temperature for 3 minutes, and perform calibration operations in the order of pH 6.86 → pH 9.18 → pH 4.01. Adjust the non-enveloped virus inactivating composition to be measured to 20 °C, immerse the electrode of the above pH meter in the sample, and measure the pH after 1 minute.

[0060] The non-enveloped virus inactivating composition of the present invention can be used, for example, in a liquid, gel, or paste form. Depending on their usage forms, the non-enveloped virus inactivating composition of the present invention can appropriately contain solubilizing carriers such as water and solvents, and gelling agents.

[0061] The non-enveloped virus inactivation composition of the present invention may be used for (1) human purposes, such as on human skin, fingers, hair, and oral cavity; (2) food purposes, such as on the surface of food materials such as vegetables; (3) hard articles; (4) textile products, such as cloth, yarn, and other textile materials and products manufactured using these; and (5) livestock, such as cattle, pigs, and birds. Examples of hard articles include hard articles with hard surfaces, such as bathrooms, toilets, kitchens, floors, doorknobs, tableware, food processing equipment, desks, chairs, and walls. These hard articles may be used in homes, public facilities, factories, such as swimming pools, bathhouses, restaurants, hospitals, and livestock facilities. The non-enveloped virus inactivation composition of the present invention may be used for hard surfaces.

[0062] <Method for inactivating non-enveloped viruses> The present invention provides a method for inactivating non-enveloped viruses, which involves contacting the non-enveloped virus inactivation composition of the present invention with a target surface. In the method for inactivating non-enveloped viruses of the present invention, the non-enveloped virus inactivation composition to be brought into contact with the target surface may be appropriately adapted from the embodiments described in the description of the non-enveloped virus inactivation composition of the present invention.

[0063] The target surfaces for the non-enveloped virus inactivation method of the present invention may include (1) the body, such as human skin, fingers, hair, and oral cavity; (2) food, such as the surface of food materials such as vegetables; (3) hard articles; (4) textile products, such as cloth, yarn, and other textile materials and products manufactured using these; and (5) livestock, such as cattle, pigs, and birds. Examples of hard articles include hard articles with hard surfaces such as bathrooms, toilets, kitchens, floors, doorknobs, tableware, food processing equipment, desks, chairs, and walls. These hard articles may be used in homes, public facilities, factories, such as swimming pools, bathhouses, restaurants, hospitals, and livestock facilities. The target surfaces for the non-enveloped virus inactivation method of the present invention may be hard surfaces.

[0064] In the method for inactivating non-enveloped viruses of the present invention, a concentrated composition containing components (a) and (b) of the present invention may be prepared in advance, and the concentrated composition may be diluted with water to prepare the non-enveloped virus inactivation composition of the present invention, which may then be brought into contact with the target surface. That is, the method for inactivating non-enveloped viruses of the present invention may also be a method for inactivating non-enveloped viruses in which a concentrated composition containing components (a) and (b) of the present invention is diluted with water to prepare the non-enveloped virus inactivation composition of the present invention, and the non-enveloped virus inactivation composition is brought into contact with the target surface without dilution.

[0065] One method for bringing the non-enveloped virus inactivation composition of the present invention into contact with a target surface is to bring the non-enveloped virus inactivation composition of the present invention into contact with a target surface where non-enveloped viruses are present or are suspected to be present. Methods for bringing the non-enveloped virus inactivation composition into contact include spraying or coating, or immersing the target surface, such as a textile product, in the non-enveloped virus inactivation composition of the present invention. Alternatively, the non-enveloped virus inactivation composition of the present invention may be impregnated into a nonwoven fabric and then brought into contact with the target surface.

[0066] When spraying or applying the non-enveloped virus inactivation composition of the present invention to a target surface, the non-enveloped virus inactivation composition of the present invention may be filled into a container equipped with a sprayer and sprayed in the form of droplets or foam, or the non-enveloped virus inactivation composition of the present invention may be poured from the container onto the target surface and applied with a brush or the like. Examples of containers equipped with a sprayer include trigger-type spray containers, pump-type spray containers and other manual spraying devices that do not use propellants, and aerosols that use propellants. The container equipped with the sprayer is preferably a trigger-type spray capable of spraying the contents in droplet or foam form, and more preferably a trigger-type spray equipped with a mechanism for spraying the contents in droplet form or a mechanism for forming foam (foam-forming mechanism).

[0067] When immersing a target surface, such as a textile product, in the non-enveloped virus inactivation composition of the present invention, the target surface and the non-enveloped virus inactivation composition of the present invention may be left undisturbed or stirred during immersion. When stirring the non-enveloped virus inactivation composition of the present invention, it may be stirred by hand or a rotary stirrer may be used. A rotary stirrer is a device that stirs the target surface and the non-enveloped virus inactivation composition of the present invention by rotating them around a certain axis of rotation. The rotary stirrer may stir in only one direction or in the opposite direction. Furthermore, stirring can be performed continuously or intermittently. Examples of rotary stirrs available to users include pulsator-type washing machines, agitator-type washing machines, or drum-type washing machines.

[0068] When impregnating a nonwoven fabric with the non-enveloped virus inactivation composition of the present invention and bringing it into contact with a target surface, the nonwoven fabric can be processed into a sheet, and it is preferable that the fibers constituting the nonwoven fabric consist of one or more fibers selected from hydrophilic fibers and hydrophobic fibers. In this invention, hydrophilic fibers refer to fibers with a moisture content (at 20°C, 65%RH) exceeding 5% by mass under standard conditions. The moisture content under standard conditions is measured by the methods specified in JIS L 1013 and JIS L 1015. Hydrophobic fibers refer to fibers with a moisture content (at 20°C, 65%RH) of 5% by mass or less under standard conditions. The method for bringing the composition into contact with the target surface involves pressing a nonwoven fabric impregnated with the non-enveloped virus inactivation composition of the present invention against the target surface and applying external force within a range that does not damage the object, thereby bringing the non-enveloped virus inactivation composition impregnated in the nonwoven fabric into contact with the target surface. This can be done by rubbing, kneading, or tapping.

[0069] The time for which the non-enveloped virus inactivating composition of the present invention is in contact with the target surface (the time it is left standing) is preferably 30 seconds or more, more preferably 1 minute or more, even more preferably 5 minutes or more, and preferably 120 minutes or less, more preferably 60 minutes or less, and even more preferably 10 minutes or less, from the viewpoint of the non-enveloped virus inactivating effect. After contact, you can let it dry as is, wipe it with a clean cloth, or rinse it with water. When rinsing, you can apply external force (physical force) with a sponge or simply rinse it with a stream of water.

[0070] <Enhancing agent for the inactivation effect of cationic surfactants on non-enveloped viruses> The present invention provides an enhancer for the non-enveloped virus inactivation effect of a cationic surfactant, comprising (b) an aromatic alcohol with a CLogP of 1.4 or more and 2.0 or less [hereinafter referred to as component (b)]. As component (b) in the non-enveloped virus inactivation effect enhancer of the cationic surfactant of the present invention, the embodiment of component (b) described in the non-enveloped virus inactivation composition of the present invention can be appropriately applied. Furthermore, the cationic surfactant non-enveloped virus inactivation effect enhancer of the present invention may be a cationic surfactant non-enveloped virus inactivation effect enhancer that enhances the non-enveloped virus inactivation effect of the cationic surfactant described as component (a) in the non-enveloped virus inactivation composition of the present invention. Furthermore, the cationic surfactant non-enveloped virus inactivation effect enhancer of the present invention may be, for example, a cationic surfactant non-enveloped virus inactivation effect enhancer that is used in a composition containing component (a) in the amount described in the non-enveloped virus inactivation composition of the present invention, and enhances the non-enveloped virus inactivation effect of component (a) contained in the composition. Furthermore, the virus that component (a) inactivates is a non-enveloped virus as described in the non-enveloped virus inactivation composition of the present invention, but the non-enveloped virus inactivation composition of the present invention can also inactivate enveloped viruses. Therefore, the enhancer of the non-enveloped virus inactivation effect of the cationic surfactant of the present invention may be an enhancer of the virus inactivation effect of the cationic surfactant.

[0071] The enhancer for the non-enveloped virus inactivation effect of the cationic surfactant of the present invention may contain component (b) in an amount of preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and even more preferably 1.0% by mass or more, from the viewpoint of non-enveloped virus inactivation effect, and preferably 100% by mass or less, more preferably 50% by mass or less, and even more preferably 20% by mass or less, from the viewpoint of formulation stability. The enhancer for the non-enveloped virus inactivation effect of the cationic surfactant of the present invention may be a composition comprising component (b).

[0072] Furthermore, the cationic surfactant non-enveloped virus inactivation effect enhancer of the present invention can be used with component (a) or a composition containing component (a) such that, from the viewpoint of non-enveloped virus inactivation effect, the mass ratio (a) / (b) of component (a) to component (b) is preferably 0.0001 or more, more preferably 0.0002 or more, even more preferably 0.0005 or more, even more preferably 0.0008 or more, even more preferably 0.0010 or more, and preferably 5 or less, more preferably 1 or less, even more preferably 0.1 or less, and even more preferably 0.05 or less.

[0073] <Method to enhance the non-enveloped virus inactivation effect of cationic surfactants> The present invention provides a method for enhancing the non-enveloped virus inactivation effect of a cationic surfactant by (a) adding an aromatic alcohol with a CLogP of 1.4 to 2.0 [component (b)] to a non-enveloped virus inactivation composition containing a cationic surfactant [component (a)]. In the method for enhancing the non-enveloped virus inactivation effect of the cationic surfactant of the present invention, the embodiments described in the non-enveloped virus inactivation composition of the present invention can be appropriately applied as component (a) and component (b). Furthermore, a method for enhancing the non-enveloped virus inactivation effect of the cationic surfactant of the present invention may be, for example, a method for enhancing the non-enveloped virus inactivation effect of the cationic surfactant, which is used in a composition containing component (a) in the amount described in the non-enveloped virus inactivation composition of the present invention, and enhances the non-enveloped virus inactivation effect of component (a) contained in the composition. Furthermore, in the method for enhancing the non-enveloped virus inactivation effect of the cationic surfactant of the present invention, component (b) can be used such that the mass ratio of component (a) to component (b) is (a) / (b), as described in the description of the enhancer for the non-enveloped virus inactivation effect of the cationic surfactant of the present invention. Furthermore, the virus that component (a) inactivates may be an enveloped virus, not only the non-enveloped virus described in the non-enveloped virus inactivation composition of the present invention. Therefore, the method for enhancing the non-enveloped virus inactivation effect of the cationic surfactant of the present invention may be a method for enhancing the virus inactivation effect of the cationic surfactant. [Examples]

[0074] <Composition ingredients> The following components were used in the examples, comparative examples, and formulation examples. <(a) Components> a-1: Benzalkonium chloride, Sanizol 50 (manufactured by Kao Corporation), general formula (a2), R 5a However, it is an alkyl group with 12 or more carbon atoms and 16 or less, R 6a and R 7a The group is a methyl group, X - It is a compound of chloride ions. a-2: Didecyldimethylammonium chloride (manufactured by Kao Corporation), general formula (a1), R 1a and R 2a However, it is an alkyl group with 10 carbon atoms, R3a and R 4a However, it is a methyl group, X - It is a compound of chloride ions.

[0075] <(b) Component> • b-1: 2-Methylbenzyl alcohol (1.553), manufactured by Tokyo Chemical Industry Co., Ltd. • b-2: 3-Methylbenzyl alcohol (1.603), manufactured by Tokyo Chemical Industry Co., Ltd. • b-3: 4-methylbenzyl alcohol (1.603), manufactured by Tokyo Chemical Industry Co., Ltd. • b-4: 1-phenyl-1-propanol (1.942), manufactured by Tokyo Chemical Industry Co., Ltd. • b-5: 1-(p-tolyl)ethanol (1.912), manufactured by Tokyo Chemical Industry Co., Ltd. • b-6: 1-hydroxyindan (1.518), manufactured by Tokyo Chemical Industry Co., Ltd. • b-7: 3-phenyl-1-propanol (1.712), manufactured by Tokyo Chemical Industry Co., Ltd. • b-8: Cinnamyl alcohol (1.60g), manufactured by Tokyo Chemical Industry Co., Ltd. Note that the numbers in parentheses in components (b) and (b') are the values ​​of CLogP.

[0076] <(b') component> ·b'-1: Benzyl alcohol (1.104), manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. • b'-2: 2-phenylethanol (1.333), manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. · b'-3: 2-Phenoxyethanol (1.188), manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. • b'-4:2-hydroxyindan (1.218), manufactured by Tokyo Chemical Industry Co., Ltd. • b'-5: 1,2-dihydroxyindan (0.356), manufactured by Tokyo Chemical Industry Co., Ltd.

[0077] <(c) component> • c-1: Sodium dodecyl sulfate (SDS) • c-2: Polyoxyethylene alkyl ether (alkyl group with 12-14 carbon atoms, average number of added moles: 3), Softanol 30 (manufactured by Nippon Shokubai Co., Ltd.) • c-3: Lauryldimethylamine oxide, Anchitol 20N (manufactured by Kao Corporation) • c-4: Lauramidopropyl betaine, Amhithol 20AB (manufactured by Kao Corporation) <(d) component> • d-1: Diethylene glycol monobutyl ether (butyl diglycol) ·d-2:2-propanol <Other> ·SM buffer: 0.58% NaCl, 0.2% MgSO4·7H2O, 50mM Tris-HCl (pH 7.5)

[0078] <Example 1 and Comparative Example 1: Bacteriophage MS2 Evaluation Method> (1) Preparation of bacterial suspension Escherichia coli NBRC 13965 (obtained from NBRC) was inoculated onto standard agar medium (Nissui Pharmaceutical Co., Ltd.) and cultured at 37°C for 24 hours. 12 mL of LB medium (BD Difco LB Broth, Lennox) was dispensed into a cell culture flask, the resulting single colonies were suspended, and the cells were cultured at 37°C and 200 rpm with shaking for 24 hours. 12 mL of LB medium was dispensed into a new cell culture flask, 100 μL of the resulting culture solution was added, and the cells were cultured at 37°C and 200 rpm until the OD600 value reached 0.3 to prepare a bacterial suspension for double-plate agar medium preparation.

[0079] (2) Preparation of double agar plates A lower layer agar medium was prepared by pouring 25 mL of autoclaved LB agar medium (agar concentration 1.5% by mass) into a rectangular petri dish (120 × 120 × 17 mm, Greiner Japan) and allowing it to cool and solidify. A double-layer agar medium was prepared by adding 4.0 mL of the bacterial suspension from (1) to 36 mL of autoclaved LB soft agar medium (agar concentration 0.6% by mass) that had been kept warm at 50°C, stirring quickly, and pouring 15 mL onto the lower layer agar medium prepared earlier.

[0080] (3) Contact between non-enveloped virus inactivation composition and non-enveloped virus Each 1.5 mL plastic tube contains 990 μL of the non-enveloped virus inactivation composition shown in Table 1, and 1.0 × 10⁶ 11 10 μL of Escherichia coli phage MS2 NBRC 102619 (obtained from NBRC) at pfu / mL was added and thoroughly mixed, then allowed to stand for 5 minutes to allow contact between the non-enveloped virus inactivation composition and the non-enveloped virus. 10 μL of the above mixture was taken and added to 990 μL of neutralization medium to stop contact between the non-enveloped virus inactivation composition and the non-enveloped virus. The mixture of the above mixture and the neutralization medium was then further serially diluted (10 to 1,000,000 times) with SM buffer to prepare samples for spot tests. A control sample was prepared by performing the same procedure using SM buffer instead of the non-enveloped virus inactivation composition.

[0081] (4) Evaluation of non-enveloped virus inactivation effect by spot testing The samples prepared in (3) were spotted in 5.0 μL portions onto the double agar plates prepared in (2) and incubated at 37°C for 24 hours. The dilution ratio at which the death of E. coli (plaque) caused by viral infection was no longer observed was visually confirmed, and the non-enveloped virus inactivation effect of the non-enveloped virus inactivation composition was evaluated by comparing it with the results of the control sample. The evaluation results of the non-enveloped virus inactivation effect are shown in Table 1.

[0082] In Table 1, the MS2 inactivation effect (Δlog) is defined by the following formula. MS2 inactivation effect (Δlog) = LogC - LogS C: Dilution ratio at which no E. coli in the control sample was found to be dead. S: Dilution ratio at which the elimination of E. coli in the test sample was no longer observed. The larger the value of the MS2 inactivation effect (Δlog), the higher the non-enveloped virus inactivation effect of the non-enveloped virus inactivation composition.

[0083] [Table 1]

[0084] In Table 1, the content of component (a) is expressed as parts per million based on the non-enveloped virus inactivation composition. The content of component (b) is expressed as mass percent based on the non-enveloped virus inactivation composition. That is, the non-enveloped virus inactivation composition shown in Table 1 in (3) above is a composition containing components (a) and (b) as constituent components, with the remainder being water. The pH of the non-enveloped virus inactivation compositions shown in Table 1 at 20°C is in the range of 6 to 8.

[0085] As shown in Table 1, the non-enveloped virus inactivation composition of the example containing component (a) and component (b) has a higher non-enveloped virus inactivation effect than the non-enveloped virus inactivation composition of the comparative example.

[0086] Table 2 shows examples of formulations for the non-enveloped virus inactivation compositions of the present invention. Each of the non-enveloped virus inactivation compositions in Table 2 exhibits a high non-enveloped virus inactivation effect against non-enveloped viruses. The non-enveloped virus inactivation compositions shown in Table 2 contain (a) and (b), and optionally contain component (c) or (d), with the remainder being water. The pH of the non-enveloped virus inactivation compositions shown in Table 2 at 20°C is in the range of 6 to 8.

[0087] [Table 2]

Claims

1. A non-enveloped virus inactivation composition comprising: (a) a cationic surfactant (hereinafter referred to as component (a)); (b) an aromatic alcohol having a CLogP of 1.4 or more and 2.0 or less (hereinafter referred to as component (b)); and water.

2. 2. The non-enveloped virus inactivating composition according to claim 1, wherein component (a) is a quaternary ammonium salt surfactant having one or two alkyl groups each having from 8 to 16 carbon atoms, and the remainder being a group selected from an alkyl group having from 1 to 3 carbon atoms, a hydroxyalkyl group having from 1 to 3 carbon atoms, and a benzyl group.

3. 2. The non-enveloped virus inactivating composition according to claim 1, wherein component (a) is one or more compounds selected from the group consisting of a compound represented by the following general formula (a1) and a compound represented by the following general formula (a2): 【Chemical 1】 [In the formula, R １ａ is an aliphatic hydrocarbon group having 8 to 18 carbon atoms, and R ２ａ is a group selected from an aliphatic hydrocarbon group having from 8 to 18 carbon atoms, an alkyl group having from 1 to 3 carbon atoms, and a hydroxyalkyl group having from 1 to 3 carbon atoms, and R ３ａ and R ４ａ are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X － is an anion. 【Chemistry 2】 [In the formula, R ５ａ is an aliphatic hydrocarbon group having 8 to 18 carbon atoms, and R ６ａ and R ７ａ are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X － is an anion.

4. 2. The non-enveloped virus inactivating composition according to claim 1, wherein the molecular weight of component (b) is 120 or more and 200 or less.

5. 2. The non-enveloped virus inactivating composition according to claim 1, wherein the content of component (a) is 10 ppm or more and 10,000 ppm or less.

6. 2. The non-enveloped virus inactivating composition according to claim 1, wherein the pH of the non-enveloped virus inactivating composition at 20°C is 4 or higher and 10 or lower.

7. The non-enveloped virus inactivating composition according to claim 1, wherein the non-enveloped virus is a virus belonging to the Norovirus genus.

8. A method for inactivating non-enveloped viruses, comprising contacting a target surface with the non-enveloped virus inactivating composition according to any one of claims 1 to 7.

9. (b) An enhancer for the non-enveloped virus inactivation effect of a cationic surfactant, which comprises an aromatic alcohol having a CLogP of 1.4 or more and 2.0 or less.

10. A method for enhancing the non-enveloped virus inactivation effect of a cationic surfactant by adding (b) an aromatic alcohol having a CLogP of 1.4 or more and 2.0 or less to a non-enveloped virus inactivation composition containing (a) a cationic surfactant.

Images